Biofourmis develops and delivers clinically validated software-based therapeutics to provide cost-effective solutions for payers, accelerated research and drug development for biopharmaceutical companies, advanced tools for clinicians to deliver personalized care, and, ultimately, better outcomes for patients.
Our robust digital therapeutics products and pipeline covers multiple therapeutic areas including heart failure, acute coronary syndrome, COPD, and chronic pain.
At the heart of Biofourmis is our clinically-proven and FDA-cleared Biovitals™ Analytics Engine. It is part of a highly sophisticated AI-powered health analytics ecosystem that predicts clinical exacerbation in advance of a critical event. It allows clinicians to deliver more personalized care and enables better patient outcomes. It can help you, too.
Biovitals™ can help prevent disease, manage complex chronic populations, and minimize unnecessary readmissions and ER visits.
Biovitals™ enables near real-time monitoring and management of patients to measure effectiveness, dosage variances, and adverse reactions at the individual level. All the data you need to show benefits and risks and the overall value of your treatment versus current options.
Biovitals™ can make it clear which treatments are working for which patients, so you can take a more personalized approach to your reimbursement strategy.
Biofourmis gives you proven, AI-powered tools and insight with the potential to improve clinical outcomes for your patients. The predictive capabilities of the Biovitals™ platform enable you to take early action and deliver more personalized care.
Biofourmis collaborators with some of the world’s most respected healthcare organizations, research hospitals, and biopharma companies. Together, we’re reducing healthcare costs, accelerating drug research and development, and improving patient outcomes.
Biofourmis' cross-functional team operates at the intersection of data science, biotechnology, and software technology with proven experience at well-known healthcare organizations, including Philips, Roche, Novartis, Abbott, MIT, GE Healthcare, and Johns Hopkins.
Let’s get you up to speed on all things Biofourmis.
BOSTON, October 3, 2019 – Biofourmis, a fast-growing global leader in digital therapeutics, has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its machine-learning and artificial intelligence (AI)-powered Biovitals™ Analytics Engine as a medical device for ambulatory physiological monitoring. This regulatory approval of the Biovitals™ Analytics Engine is part of FDA's growing recognition of machine-learning and AI in the Software as a Medical Device category.
October 3, 2019
NEW YORK, Oct. 2, 2019 /PRNewswire/ -- CB Insights announced today at its Future of Health conference that Biofourmis, a Boston-based fast-growing global leader in digital therapeutics, has been named to the organization's inaugural Digital Health 150 ranking, which showcases the 150 most promising private digital health companies in the world. Kuldeep Singh Rajput, CEO and founder of Biofourmis, will be speaking at the Future of Health conference—a gathering of top executives across some of the largest healthcare institutions, startups and investment firms—taking place here today and tomorrow.
October 2, 2019
BOSTON, Aug. 22, 2019 /PRNewswire/ -- Biofourmis, a fast-growing global leader in digital therapeutics based in Boston, has added two global pharmaceutical senior executive veterans to its executive team to guide the company's worldwide expansion across the pharmaceutical, managed care, healthcare provider and medical technology markets.
August 22, 2019
Biofourmis offers a powerful patented AI-based platform for therapeutic decision support. It continuously analyzes data from medical-grade wearable sensors and other patient-generated data to create unique digital biomarkers reflecting the health status of an individual. These digital biomarkers have been assessed in several studies and have demonstrated the ability to help detect changes in an individual’s health status much earlier than previously possible.
July 30, 2019
In collaboration with the FDA and our partner Biofourmis, Biovotion’s Everion will play a critical role in a new trial aimed at improving outcomes and evaluating new endpoints for heart failure patients. Leveraging Biofourmis’ AI-enabled platform, BiovitalsHF, data collected from discharged patients will be used to develop new methods of evaluating the efficacy of heart failure drugs.
July 19, 2019
BOSTON, July 16, 2019 /PRNewswire/ -- Biofourmis, a fast-growing global leader in digital therapeutics, has entered a research partnership with the Yale University-Mayo Clinic Center of Excellence in Regulatory Science and Innovation (CERSI). Biofourmis' mobile platform BiovitalsHFTM will be leveraged in a study of patients with heart failure to monitor functional capacity and quality of life to see if greater emphasis should be placed on these measures in the drug approval process.
July 16, 2019
A collaboration involving the FDA is set to evaluate new endpoints for heart failure clinical trials. The partners will use wearable devices to assess how heart failure patients function and feel after being discharged from hospitals.
July 16, 2019
Start-ups such as Boston-based Biofourmis have partnered with local health care platforms like Jianke, giving the company access to its vast customer base
June 9, 2019
Biofourmis, a Singapore-based startup pioneering a distinctly tech-based approach to the treatment of chronic conditions, has raised a $35 million Series B round for expansion. The round was led by Sequoia India and MassMutual Ventures, the VC fund from Massachusetts Mutual Life Insurance Company. Other investors who put in include EDBI, the corporate investment arm of Singapore’s Economic Development Board, China-based healthcare platform Jianke and existing investors Openspace Ventures, Aviva Ventures and SGInnovate, a Singapore government initiative for deep tech startups. The round takes Biofourmis to $41.6 million raised to date, according to Crunchbase.
May 21, 2019
The RhythmAnalytics platform can integrate with medical devices and other ECG management systems to detect arrhythmias.
May 3, 2019
Congratulations to our Founder and CEO Kuldeep Singh Rajput for making it into the Forbes Asia 30 Under 30 list for Healthcare and Science 2019! We're excited to celebrate this well-deserved achievement as we continue on our mission to predict and prevent critical medical events before they happen!
May 3, 2019
BOSTON, March 13, 2019 /PRNewswire/ -- Biofourmis, a fast-growing digital therapeutics company focused on augmenting personalized care and therapies to empower patients with complex chronic conditions, today joined the American Heart Association's Center for Health Technology & Innovation's (Center) Innovators Network to deliver personalized software-based intervention including dose changes, heart failure education and insights to patients with heart failure.
March 13, 2019
Biofourmis, a Singapore-based health analytics platform, has entered into a collaboration with Brigham and Women’s Hospital in Boston, US to co-develop improvements to their proprietary analytics engine, Biovitals™ for Brigham’s Home Hospital Programme.
November 22, 2018
Mundipharma has announced the development of painfocus™, a revolutionary new end-to-end pain management solution that significantly increases the objectivity of pain measurement, something that has been historically difficult. This has the potential to completely transform how caregivers and doctors manage their patients' pain.
August 5, 2018
Our COO Karen Wai will be speaking at Echelon Asia Summit 2018 (28 June) on the Topic: “Tackling health problems using AI: Why data analytics will play a big role in healthcare.”
June 21, 2018
Singapore-based health analytics platform Biofourmis announced the close of its series A funding round today, while also unveiling a partnership with US medical research institute, the Mayo Clinic.
December 11, 2017
SINGAPORE - Singapore-based digital healthtech firm Biofourmis has raised US$5 million (S$6.8 million) in a Series A round of funding from venture capital firm NSI Ventures and Aviva Ventures, the corporate venture arm of insurer Aviva.
December 11, 2017
The company bills itself as the world’s first personalized physiological data analytics firm, and today it announced a fundraise of US$1 million. The round was led by healthcare technology company SpesNet and social innovation firm Eden Strategy. It was joined by angel investors from the healthcare space.
August 10, 2016
Biofourmis, Singapore-based personalised physiological data analytics firm, today announced that the company has secured US$1 million in angel funding, led by SpesNet and Eden Strategy. Biofourmis has been actively working with the healthcare sector to offer predictive, precise and meaningful insights into one’s health.
August 10, 2016
Together, we’ll explore what’s possible for your organization.